Competition
Competition — who can hurt Convatec, and who Convatec can beat
Competitive Bottom Line
Convatec has a real but uneven moat: very strong in Infusion Care (where it is the only listed pure-play OEM to the global durable insulin-pump industry), structurally narrower in Advanced Wound Care (a 6% share of a $13bn arena dominated by Smith+Nephew, Solventum and private Mölnlycke), and credible-but-second-best in Ostomy and Continence (15–20% global share against Coloplast's 35–45%). The one competitor that matters most is Coloplast — same chronic-care consumables business model, ~570bps higher operating margin, ~3× the equity value, and a stated ambition to take a "larger share" of Wound & Tissue Repair as well. The real risk is not displacement; it is that Convatec stays a permanent #2 with permanent #2 multiples.
The competitive question is not "can Convatec survive?" — it is "can Convatec close half the gap to Coloplast?" Survival is not in dispute: chronic-care consumables are demographically driven, regulatorily moated, and switching costs are medical not financial. The valuation argument is whether the 22.3% adj. op margin can converge toward Coloplast's 28% over 2026–28, and whether share losses in skin-substitutes (Coloplast/Kerecis) and tubeless insulin (Insulet) stay contained.
The Right Peer Set
The right peer set is built around direct economic substitutes per franchise, not by index or sub-industry code. Convatec faces a different competitor profile in each of its four franchises, and a single all-in-one peer table flatters one franchise and misleads on another. Five comparators do most of the work — Coloplast (mirror business model), Smith+Nephew (the AWM benchmark), Solventum (AWC + NPWT incumbent), Insulet (the only true substitute, in Infusion Care), and ICU Medical (Critical Care infusion adjacency) — with Becton Dickinson and Embecta as anchor and mini-comp.
Two notes on the table. (1) Coloplast EV is shown as N/A — the staged source (CompaniesMarketCap, 2026-05-05) does not report it; treat the ~$14.4bn market cap as the comparator and back out an EV from the FY24/25 AR (DKK 6.6bn net debt → ~$1bn USD; implied EV ~$15.4bn). (2) SNN operating margin shown is reported (12.9%); SNN's trading (adj.) margin was 19.7% in FY25 — this is the like-for-like comparator to Convatec's 22.3% adj. op margin. Always read SNN twice.
The bubble chart hides the most useful insight: Convatec is one of only two listed pure-plays in the chart (Coloplast is the other), and the other "pure-plays" on the chart are not really comparators — Insulet sells a competing technology to Convatec's infusion sets; Embecta is a declining diabetes-injection asset; ICU Medical is a hospital-capital-equipment integrator with structurally lower margin. The real read across the chart is the vertical gap to Coloplast (5.7pts of margin, $9.6bn of equity value at similar growth) — that is the entire bull case for re-rating.
The listed peer set understates the true industry consolidation because the two largest non-Coloplast Ostomy/Continence competitors (Hollister Inc. and Mölnlycke Health Care) are private — Hollister is a US-strong incumbent in ostomy; Mölnlycke is a top-3 advanced wound care player (Sweden, owned by Investor AB). Excluding them inflates the share that public peers appear to hold. Treat any public-only share table as a lower bound on consolidation.
Where The Company Wins
Four advantages stand up to evidence — three structural, one strategic. None of them are unique gross-margin claims; all of them concern commercial structure or asset position that competitors cannot quickly replicate.
The heatmap shows the strategic asymmetry that the listed peer table does not: Convatec is the only company in the comparator set that is present in all four chronic-care franchises, and the only one with a leadership position in the high-growth Infusion Care arena that competitors do not enter at all. Coloplast is bigger overall but not in IC; Smith+Nephew is dominant in AWM but absent from Ostomy/Continence/IC; Solventum and Insulet are single-franchise plays. The diversification bull case is the IC franchise, not a generic "we cover the patient journey" claim — IC is what differentiates Convatec from Coloplast at multiples-relevant scale.
Where Competitors Are Better
Four real disadvantages to underwrite. Be specific: each names which competitor, what the gap is, and why it matters.
The AWM chart is the single most uncomfortable competitive fact in this report. Convatec's largest revenue franchise (AWC, 31% of group) is fourth globally in the market it competes in. Each of the leaders has either greater scale (SNN, SOLV) or stronger biologic technology (SOLV NPWT, Mölnlycke foam dressings) or both. The Advanced Wound Care growth thesis at Convatec rests on out-launching the leaders rather than out-spending them — ConvaFoam launch, ConvaNiox NO-therapy launch, antimicrobial Aquacel extensions — which is execution risk, not a structural moat.
Threat Map
Six threats, scored on severity and timing. Two are reimbursement events (high near-term but already largely guided), two are competitor actions (medium severity, slower-burning), one is a regulatory quality risk, and one is private-company encroachment.
The asymmetry on the threat chart matters. The two highest-severity threats (FDA Warning Letter escalation, DMEPOS CBP) are both regulatory events with discrete triggers and known timelines — they can be monitored and largely resolved or sized within 12–24 months. The slower-burning threats (Insulet substitution, SNN/SOLV AWC scale) are continuous and harder to detect — they show up as 50–100bps of organic growth lost per year, not as a press release. The cheap mistake is to focus the moat thesis on the visible regulatory threats while quietly losing share to the invisible competitive ones.
Moat Watchpoints
Five measurable signals to watch over the next 12–24 months. If three or more move against Convatec, the moat thesis weakens; if three or more move with Convatec, the margin-convergence-to-Coloplast story strengthens.
Bottom line for the moat. Convatec has a real, defensible position in Infusion Care, a credible second-place position in Ostomy and Continence, and an honestly weak fourth-place position in Advanced Wound Care. The competitive case is not whether the moat exists — it does — but whether the commercial productivity gap to Coloplast (~570bps of margin) closes meaningfully, and whether DMEPOS CBP 2028 becomes a winner's tailwind or an industry-wide reset. Watch Coloplast's read-across, Insulet's patient adds, and Convatec's own margin walk. Everything else (FX, share price, sell-side ratings) is noise.